FDA medical device cybersecurity updates
US Food and Drug Administration
Every FDA cybersecurity guidance, rule and draft that affects medical device 510(k), De Novo, and PMA submissions, with a short summary of each and what manufacturers should do.
- Feb 3, 2026·Final GuidanceActiveHigh impact
FDA finalizes 2026 premarket cybersecurity guidance
The FDA's February 3, 2026 final guidance distinguishes nonbinding cybersecurity evidence recommendations from Section 524B statutory duties. Covered cyber-device submissions require an SBOM; VEX is optional, and an SPDF is encouraged rather than mandated.
Read details - Feb 3, 2026·Guidance supersededWithdrawnMedium impact
FDA 2023 premarket cybersecurity guidance superseded
The September 2023 premarket cybersecurity guidance is superseded by the February 3, 2026 final guidance. Citing the 2023 document in new submissions is now a stale reference.
Read details - Feb 2, 2026·Final RuleActiveHigh impact
FDA Quality Management System Regulation (QMSR) takes effect
The QMSR formally aligns 21 CFR Part 820 with ISO 13485:2016. Cybersecurity design controls, risk management, and supplier controls must now be documented under the harmonized framework.
Read details - Jan 7, 2025·Draft GuidanceDraftMedium impact
FDA draft guidance on AI-enabled device software functions (2025)
This draft covers lifecycle management and what to include in marketing submissions for AI-enabled device software, including a section on cybersecurity risks specific to AI, such as tampered training data and attacks on model inputs.
Read details - Dec 4, 2024·Final GuidanceActiveHigh impact
FDA finalizes Predetermined Change Control Plans (PCCP) guidance
Final PCCP guidance lets manufacturers pre-authorize specified modifications to AI/ML-enabled device software functions without a new submission, provided cybersecurity impacts are scoped up front.
Read details - Mar 13, 2024·Draft GuidanceWithdrawnLow impact
FDA Draft Section 524B Guidance Updates (2024)
In March 2024 the FDA published a draft explaining how it reads Section 524B, including what counts as a cyber device. That content has since been brought into the final premarket cybersecurity guidance.
Read details - Jun 14, 2023·Final GuidanceActiveMedium impact
FDA Device Software Functions Guidance (2023)
This guidance sets out the software documentation the FDA expects in a premarket submission, using two levels (Basic and Enhanced) based on risk. It sits alongside the cybersecurity guidance, which covers the security content.
Read details - Mar 29, 2023·StatuteActiveHigh impact
FD&C Act Section 524B - cyber device requirements in effect
Section 524B (Omnibus 2023) made cybersecurity submission content mandatory for cyber devices. The FDA has issued Refuse to Accept decisions for non-compliant submissions since October 2023.
Read details - Mar 29, 2023·Final GuidanceWithdrawnMedium impact
FDA Refuse-to-Accept Policy for Cyber Devices (2023)
When Section 524B took effect, the FDA said it would not refuse submissions for missing 524B content until October 1, 2023, and would work with sponsors during review instead. After that date, submissions missing the required cybersecurity content could be refused.
Read details - Dec 28, 2016·Final GuidanceActiveMedium impact
FDA postmarket cybersecurity guidance (2016)
The FDA's postmarket guidance describes how manufacturers should monitor, assess and fix cybersecurity vulnerabilities in devices already on the market, including when a fix needs to be reported to the FDA and when it does not.
Read details - Oct 2, 2014·Final GuidanceWithdrawnLow impact
FDA's first premarket cybersecurity guidance (2014), now superseded
The FDA's 2014 guidance was the agency's first statement of what cybersecurity content belongs in a premarket submission: a hazard analysis, a list of controls, and a plan for updates. Later premarket guidance replaced it.
Read details
Other agencies in the tracker
Secure your device before it reaches patients.
30-minute strategy session. No cost, no commitment - just answers from people who've supported 275+ FDA submissions, with zero cybersecurity rejections.